Targeted drug delivery to solid tumors aims to increase the accumulation of drug at the site of disease while limiting accumulation in healthy tissues. Thus, targeted delivery serves to enhance therapeutic efficacy while minimizing off-target side effects. Targeting drug to the site of disease is especially important for many current anti-cancer therapeutics whose cytotoxic effects are not exclusive to cancer cells. Drug carriers can improve tumor targeting of drug cargo by either passive or active mechanisms. Passive targeting of drug carriers occurs by the enhanced permeability and retention effect, whereby long circulating drug carriers can accumulate in the tumor by extravasation from the tumor;;s leaky vasculature and be retained in the tumor due to the lack of an organized tumor lymphatic system. Alternatively, active targeting can improve drug delivery to the tumor by means of functionalizing a drug carrier such that it interacts specifically with the tumor tissue. Traditionally, actively targeted drug carriers rely on intrinsic features of the tumor such as upregulated cell receptors, overexpressed extracellular enzymes, or depressed tissue pH. These intrinsic targets, however, are heterogeneous across cancer classes and between patients with a single tumor type. Therefore traditional active targeting cannot be applied to a breadth of cancers or patients without prior knowledge of the cancer phenotype.
Active targeting can alternatively be achieved by an extrinsic trigger, independent of the characteristics of the tumor. This approach could thereby achieve targeted drug delivery in a breadth of tumor types and cancer patients. This dissertation describes one such approach that exploits cell-penetrating peptides (CPPs) to achieve receptor-independent and non-specific uptake in a variety of cancer cells. The function of this non-specific CPP is controlled by an extrinsic trigger by means of the modulation of its local interfacial density with temperature-triggered micelle assembly. Elastin-like polypeptide diblock copolymers (ELPBCs) were used as the drug carrier platform, as their lower critical solution temperature phase transition behavior permits their controlled self-assembly from unimer to micelle in response to a thermal stimulus. CPP-ELPBCs were recombinantly synthesized in
Temperature-triggered micelle assembly of CPP-ELPBCs achieved controlled cellular uptake
For use as targeted drug carriers